Correlation Between the Movement Disorder Society ’s Unified Parkinson’s Disease Rating Scale and Nonmotor Scales in Patients with Parkinson’s Disease
by Erika D. Driver-Dunckley, MD; Nan Zhang, MS; Holly A. Shill, MD; Shyamal H. Mehta, MD, PhD; Christine M. Belden, PsyD; Edward Y. Zamrini, MD; Kathryn Davis; Thomas G. Beach, MD, PhD; and Charles H. Adler, MD, PhD Drs. Driver-Dunckley, Mehta, and Adler are with the Department of Neurology of the Parkinson’s Disease and Movement […]
Determination of atomoxetine or escitalopram in human plasma by HPLC: Applications in neuroscience research studies . Int J Clin Pharmacol Ther. 2020 May 25;: Authors: Teichert J, Rowe JB, Ersche KD, Skandali N, Sacher J, Aigner A, Regenthal R Abstract BACKGROUND: Atomoxetine and escitalopram are potent and selective drugs approved for noradrenergic or serotonergic modulation of neuronal networks in attention-deficit hyperactivity disorder (ADHD) or depression, respectively. High-performance liquid chromatography (HPLC) methods still play an important role in the therapeutic drug monitoring (TDM) of ...
Condition: Parkinson's Disease Interventions: Drug: Varenicline; Other: Evaluation by Investigator; Other: Placebo Sponsor: University of Michigan Completed
PARKINSON'S disease is a progressive neurological condition which means it causes problems in the brain which gets worse over time. A lot of signs of the disease lie in a person's movement, however, there are a lot of different warning signs which lie in a person's mouth. What are they?
This study provides a comprehensive analysis of un ique strain-specific interaction between oligomeric α-Syn and tau. Furthermore, this study allows us to speculate that distinct α-Syn-tau interactions inducing tau aggregation might be an underlying mechanism of neurodegeneration in PD.
Corrigendum to "Kinematic gait parameters for older adults with Parkinson's disease during street crossing simulation" [Human Movement Science 70 (2020) 102599]. Hum Mov Sci. 2020 Jun;71:102628 Authors: Amaral-Felipe KMD, Yamada PA, Abreu DCC, Freire Júnior RC, Stroppa-Marques AEZ, Hallal CZ, Faganello-Navega FR PMID: 32452444 [PubMed - in process]
(Nanyang Technological University) A promising molecular pair has offered hope that could lead to the development of a new treatment to slow down Parkinson's disease, a study by Nanyang Technological University, Singapore (NTU Singapore) and Harvard University has found.
Fifty-five (55) cm 8 Contact Extension Kit, part number M365NM3138550 - Product Usage: The Deep Brain Stimulation (DBS) System is indicated for use in bilateral stimulation of the subthalamic nucleus (STN) as an adjunctive therapy in reducing some of the symptoms of moderate to advanced levodopa-responsive Parkinson s disease (PD) that are not adequately controlled with medication.
Publication date: Available online 25 May 2020Source: The Lancet NeurologyAuthor(s): Bastiaan R Bloem, Emily J Henderson, E Ray Dorsey, Michael S Okun, Njideka Okubadejo, Piu Chan, John Andrejack, Sirwan K L Darweesh, Marten Munneke
Publication date: Available online 26 May 2020Source: Journal of EthnopharmacologyAuthor(s): Shanshan Fan, Qingsheng Yin, Dongna Li, Jing Ma, Lili Li, Shiwei Chai, Hong Guo, Zhen Yang
DiscussionThe trial will test the hypothesis that SLT is effective for the treatment of speech or voice problems in people with PD compared to no SLT. It will further test whether NHS SLT or LSVT LOUD ® provide greater benefit and determine the cost-effectiveness of both interventions.Trial registrationInternational Standard Randomised Controlled Trials Number (ISRCTN) Registry,ID: 12421382. Registered on 18 April 2016.